Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 25.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,205 shares of the company's stock after selling 3,473 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Krystal Biotech were worth $1,840,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of KRYS. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech during the 4th quarter worth approximately $95,000. Covestor Ltd increased its holdings in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. KBC Group NV increased its holdings in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after acquiring an additional 297 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after acquiring an additional 433 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after acquiring an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 13.70% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reiterated a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $211.13.

Krystal Biotech Trading Up 3.3%

KRYS traded up $4.32 during trading on Friday, reaching $136.94. 265,790 shares of the company were exchanged, compared to its average volume of 311,528. The stock has a market cap of $3.96 billion, a P/E ratio of 45.80 and a beta of 0.65. The firm has a 50 day moving average of $149.85 and a 200 day moving average of $163.23. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).